Vebreltinib

Apollomics' Phase 3 trial of uproleselan in China for relapsed or refractory acute myeloid leukemia did not show favorable benefit. Median OS was 9.3 months in the uproleselan arm vs. 14.3 months in the chemotherapy-only arm. The trial was generally well tolerated, with similar safety profiles in both arms.

Apollomics Inc. announced the results of its Phase 3 bridging trial of uproleselan in China, which did not meet its primary endpoint. The trial involved patients with relapsed or refractory acute myeloid leukemia (AML). Despite the setback, the company maintains a healthy current ratio of 2.25, suggesting adequate liquidity. Apollomics' lead program is now vebreltinib (APL-101), a c-Met inhibitor in a Phase 2 multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations.

The National Reimbursement Drug List (NRDL) faces budget pressure and competition, with 445 drugs passing formal review in 2024. Oncology, immunology, neurology, and rare diseases see strategic positioning and comparator choices as key. Contract renewals and re-negotiations are under pressure, emphasizing clear messaging and data preparation for NRDL success.

OBiS Insights pre-meeting ESMO24 report profiles 275 new, unapproved cancer drugs, classified as 40% antibody-based, 37% small molecule, and 23% mixed bag. The report excludes drugs not in abstract titles and will update during the conference. 43% of these drugs were discussed at recent ASCO24 meetings.

Avistone presented results from a clinical study combining c-MET and EGFR inhibitors in NSCLC patients at the 2024 WCLC, showing partial responses in 59.4% of patients and 75% in those with brain metastases.